Adial Pharmaceuticals (ADIL) Retained Earnings (2022 - 2024)
Adial Pharmaceuticals' Retained Earnings history spans 3 years, with the latest figure at -$79.9 million for Q3 2024.
- For Q3 2024, Retained Earnings changed N/A year-over-year to -$79.9 million; the TTM value through Sep 2024 reached -$79.9 million, changed N/A, while the annual FY2023 figure was -$68.8 million, 8.05% down from the prior year.
- Retained Earnings for Q3 2024 was -$79.9 million at Adial Pharmaceuticals, down from -$77.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$53.9 million in Q1 2022 and bottomed at -$79.9 million in Q3 2024.
- The 3-year median for Retained Earnings is -$66.0 million (2023), against an average of -$67.0 million.
- The largest YoY upside for Retained Earnings was 8.05% in 2023 against a maximum downside of 23.64% in 2023.
- A 3-year view of Retained Earnings shows it stood at -$63.7 million in 2022, then fell by 8.05% to -$68.8 million in 2023, then dropped by 16.17% to -$79.9 million in 2024.
- Per Business Quant, the three most recent readings for ADIL's Retained Earnings are -$79.9 million (Q3 2024), -$77.7 million (Q2 2024), and -$75.3 million (Q1 2024).